Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRI: AKST4290 in Diabetic Retinopathy
NCT05038020Phase 2Terminated
- Sponsor
- Alkahest, Inc.
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BI 144807 in diabetic retinopathy (DR), sponsored by Alkahest, Inc.. Started Aug 2021; status: terminated.
02
Drugs
BI 144807
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05038020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038020.